NEW
HAVEN, Conn., Feb. 27,
2025 /PRNewswire/ -- Trevi Therapeutics,
Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical
company developing the investigational therapy Haduvio™ (oral
nalbuphine ER) for the treatment of chronic cough in patients with
idiopathic pulmonary fibrosis (IPF) and refractory chronic cough
(RCC), today announced that senior management will be
attending the following investor conferences in March.
TD Cowen 45th Annual Health Care
Conference
March 3-5,
2025, Boston,
Massachusetts
Corporate Presentation: March 4, 10:30-11:00am
ET
Trevi Representatives: Lisa Delfini, Chief Financial
Officer, and Farrell Simon, Chief Commercial Officer
A Corporate presentation is available for in-person conference
attendees.
Leerink Partners Global Healthcare
Conference
March 10-12,
2025, Miami,
Florida
Corporate Presentation:
March 12, 8:00am ET
Trevi Representatives: Jennifer Good, President and
CEO, and James Cassella, Chief
Development Officer
A Corporate presentation is available for in-person conference
attendees.
Leerink Partners Mountain Meeting
March 23-26, 2025, Jackson Hole, Wyoming
Trevi
Representative: Lisa Delfini, Chief Financial Officer
A Corporate presentation is available for in-person conference
attendees.
About Trevi Therapeutics, Inc.
Trevi Therapeutics,
Inc. is a clinical-stage biopharmaceutical company developing the
investigational therapy Haduvio™ (oral nalbuphine extended-release)
for the treatment of chronic cough in patients with idiopathic
pulmonary fibrosis (IPF) and refractory chronic cough (RCC).
Haduvio acts on the cough reflex arc both centrally and
peripherally as a kappa agonist and a mu antagonist (KAMA), which
are opioid receptors that play a key role in controlling cough
hypersensitivity. Nalbuphine is not currently scheduled by the U.S.
Drug Enforcement Agency.
Chronic cough is highly prevalent in IPF patients, impacting up
to 85% of the IPF population. There are ~140,000 U.S. IPF patients
and the impact of chronic cough is significant with patients
coughing up to 1,500 times per day. This consistent cough, and any
associated damage, may lead to worsening disease, a higher risk of
progression, death, or need for lung transplant. Chronic cough also
often leads to a decline in patients' social, physical, and
psychological quality of life. There are no approved therapies for
the treatment of chronic cough in patients with IPF and current
off-label treatment options provide minimal benefit to
patients.
Refractory chronic cough affects approximately 2-3 million
adults in the U.S. and is caused by cough reflex hypersensitivity
in both the central and peripheral nerves. It is a highly
disruptive disease and accompanied by a wide range of
complications, ranging from urinary incontinence in females to
sleep disruption and social embarrassment that causes significant
social and economic burdens for patients and those around them.
There are also no approved therapies for RCC in the U.S.
Trevi intends to propose Haduvio as the trade name for oral
nalbuphine ER. Its safety and efficacy have not been evaluated by
any regulatory authority.
For more information, visit www.TreviTherapeutics.com and
follow Trevi on X (formerly Twitter) and LinkedIn.
Investor Contact
Jonathan
Carlson
Trevi Therapeutics, Inc.
(203) 654 3286
carlsonj@trevitherapeutics.com
Media Contact
Rosalia
Scampoli
914-815-1465
rscampoli@marketcompr.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/trevi-therapeutics-to-participate-in-upcoming-march-investor-conferences-302386266.html
SOURCE Trevi Therapeutics, Inc.
